Form 4: REGENXBIO CMO Sells Shares for Tax Obligations
Insider Transaction Report
REGENXBIO's Chief Medical Officer, Steve Pakola, disposed of 18,247 common shares to cover tax liabilities related to restricted stock unit vesting.
Summary
- Steve Pakola, Chief Medical Officer of REGENXBIO Inc., reported a transaction on January 2, 2026.
- He disposed of 18,247 shares of common stock.
- The shares were withheld to pay taxes upon the vesting of restricted stock units.
- The restricted stock units were originally granted on January 3, 2022, January 3, 2023, January 2, 2024, and January 2, 2025.
- The number of shares withheld was determined on January 2, 2026, based on the closing price of the issuer's common stock on December 31, 2025.
- The price per share for the disposition was $14.4.
- Following this transaction, Steve Pakola beneficially owns 192,470 shares of common stock directly.
Sentiment
Score: 5
Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a common part of executive compensation. It does not reflect a discretionary buy or sell decision based on the insider's view of the company's prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Minor dilution from the RSU vesting, but the tax withholding is a standard mechanism. No significant impact on overall share structure or value from this routine transaction.
Key Dates
| Date | Description |
|---|---|
| January 3, 2022 | Original grant date for a portion of restricted stock units. |
| January 3, 2023 | Original grant date for a portion of restricted stock units. |
| January 2, 2024 | Original grant date for a portion of restricted stock units. |
| January 2, 2025 | Original grant date for a portion of restricted stock units. |
| December 31, 2025 | Closing price of common stock used to determine shares withheld for taxes. |
| January 2, 2026 | Transaction date for disposition of shares and determination date for shares withheld. |
| January 6, 2026 | Date Form 4 was signed. |
Keywords
REGENXBIO, RGNX, Steve Pakola, Chief Medical Officer, CMO, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, RSU Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.